SCHEMBL3239737

SCHEMBL3239737

COc1ccc(Br)cc1C(=O)NC(c1ccccc1)C1(N(C)C)CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
DRD3 P35462 3/20 0.43
STAT3 P40763 1/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 1/20 0.43
GFER P55789 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 3/20 0.43
RXFP1 Q9HBX9 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3236119 0.88 NR1H4 (0.45) POLBLMNANPSR1ALDH1A1KMT2A
SCHEMBL3238270 0.87 ALDH1A1 (0.57) STAT3ALDH1A1KMT2AHPGDMEN1
SCHEMBL3239594 0.85 KCNQ3 (0.44) ALDH1A1HPGDRXFP1
SCHEMBL3240052 0.84 ALDH1A1 (0.39) POLBDRD3ALDH1A1CYP1A2CYP2C19
SCHEMBL4357362 0.83 PLK1 (0.50) LMNANPSR1ALDH1A1MAPTHSD17B10
SCHEMBL3237710 0.83 ALDH1A1 (0.42) ALDH1A1MAPTCYP2C9KMT2AHPGD
SCHEMBL3243825 0.82 TAS1R3 (0.42) ALDH1A1KMT2AHPGDMEN1RXFP1
SCHEMBL3237145 0.81 AVPR2 (0.43) LMNANPSR1ALDH1A1SMN1; SMN2MAPT
SCHEMBL3238721 0.81 ALDH1A1 (0.46) LMNAALDH1A1SMN1; SMN2KMT2AHPGD
SCHEMBL3240768 0.80 SLC6A9 (0.58) ALDH1A1KMT2AHPGDMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 POLB 2897/4885LMNA 4449/4885NPSR1 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.